Rossignol 1983.

Methods	Design: parallel group randomized trial Duration of study: not reported Follow‐up: 21 days
Participants	Country: 11 countries (France, Morocco, Mali, Senegal, Nigeria, Central African Republic, Kenya, Brazil, Peru, Mexico, Philippines) Setting: not reported Number included in study: 1100 Age: 3–79 years (only adult data included) Sex: 525 male, 345 female Inclusion criteria: people harbouring nematodes and cestodes Exclusion criteria: people receiving or who had received anthelmintics during the 21 days before commencing the study, those with an acute illness (with or without fever), pregnant females, nursing mothers, children under 3 years of age, diagnosed epilepsy cases and people with generalized active skin conditions. In general, people who experienced high sensitivity to any drug or were receiving long‐term therapy or having chronic illnesses or proteinuria Follow‐up: 230 (20.9%) Number positive for A lumbricoides: 270 Number included in review: 270
Interventions	Treatment strategy: screening and treat all included participants Group 1: albendazole 200 mg twice daily or 400 mg once daily for adults and 100 mg twice dally for children < 12 years old (n = 142) Group 2: placebo 1 tablet twice daily or 2 tablets once daily (n = 128)
Outcomes	Outcomes included:Ascaris cure rates and adverse events Outcomes not included in review: anthelmintic efficacy for T trichiura,Strongyloides stercoralis, and hookworm
Notes	Diagnostic technique: Kato‐Katz Funding support: Smith, Kline & French Laboratories
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Albendazole or placebo tablets were made available to patients according to randomised numbers under a code established by the manufacturer."
Allocation concealment (selection bias)	Unclear risk	Details not reported.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Details not reported.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Details not reported.
Incomplete outcome data (attrition bias) All outcomes	High risk	230 (20.9%) participants lost at follow‐up, and not included in review.
Selective reporting (reporting bias)	High risk	Authors described the results of placebo group just for "adult" participants.
Other bias	Unclear risk	Smith, Kline & French Laboratories and their area medical directors helped during the multicentre study and provided albendazole 100 mg and placebo tablets.